Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.

You may also be interested in...

Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)

Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.

Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues

As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend

In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts